Leprosy in French Guiana, 2015 to 2021: Dynamics of a Persistent Public Health Problem
DOI:
https://doi.org/10.2340/actadv.v103.6246Keywords:
French Guiana, Leprosy, Epidemiology, Reversal Reaction, InfliximabAbstract
A resurgence of leprosy as a public health problem in French Guiana was reported over the period 2007 to 2014, particularly among Brazilians gold miners. Prolonged multidrug therapy and reversal reactions represent a therapeutic challenge. The objective of this study was to assess the evolution of leprosy in this European overseas territory. All patients with leprosy confirmed in histopathology between 1 January 2015 and 31 December 2021 were included. A total of 86 patients were included, including 64 new cases and 22 previously diagnosed cases. Sixty patients (70%) were male, 6 cases were paediatric. Brazilian gold miners represented 44.1% of reported occupations (15/34). Maroons represented the second community (13 patients, 15%). Multibacillary and paucibacillary forms were found in 53 (71%) and 22 (29%) patients, respectively. The annual prevalence never exceeded the threshold of 1/10,000. The mean incidence and prevalence were significantly lower than during the period 2007 to 2014 (p < 0.0001). Reversal reactions were found in 29 patients and almost always required a long course of steroids. Infliximab allowed a reduction in the length of treatment with steroids in 2/2 cases. In conclusion, the prevalence of leprosy has decreased significantly in French Guiana, but remains driven by the population of illegal gold miners. Anti-tumour necrosis factor (anti-TNF) drugs represent a promising option in the management of reversal reactions.
Downloads
References
Alemu Belachew W, Naafs B. Position statement: Leprosy: diagnosis, treatment and follow-up. J Eur Acad Dermatol Venereol 2019; 33: 1205-1213.
https://doi.org/10.1111/jdv.15569 DOI: https://doi.org/10.1111/jdv.15569
Epelboin L, Chroboczek T, Mosnier E, Abboud P, Adenis A, Blanchet D, et al. L'infectiologie en Guyane : le dernier bastion de la médecine tropicale française. La lettre de l'Infectiologue 2016; XXXI.
Graille J, Blaizot R, Darrigade AS, Sainte-Marie D, Nacher M, Schaub R, et al. Leprosy in French Guiana 2007-2014: a re-emerging public health problem. Br J Dermatol 2020; 182: 237-239.
https://doi.org/10.1111/bjd.18334 DOI: https://doi.org/10.1111/bjd.18334
World Health Organization Expert Committee on Leprosy. Seventh report. Geneva: World Health Organization; 1998.
Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Mycobact Dis Off Organ Int Lepr Assoc 1966; 34: 255-273.
Reibel F, Cambau E, Aubry A. Histoire et actualité du traitement de la lèpre. J Anti-Infect 2015; 17: 91-98.
https://doi.org/10.1016/j.antinf.2015.01.004 DOI: https://doi.org/10.1016/j.antinf.2015.01.004
Sansarricq, Hubert & UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. 2006. Polychimiothérapie contre la lèpre: développement et mise en oeuvre depuis 25 ans. Organisation mondiale de la Santé. [accessed 24/04/2023] Available from: https://apps.who.int/iris/handle/10665/69318.
Domergue V, Clyti E, Sainte-Marie D, Huber F, Marty C, Couppié P. La lèpre en Guyane française: étude rétrospective de 1997 à 2006. Med Trop 2008; 68: 7.
World Health Organization. Global leprosy (Hansen disease) update, 2020: impact of COVID-19 on the global leprosy control. [accessed 24/04/2023] Available from https://www.who.int/publications-detail-redirect/who-wer9636-421-444.
Douine M, Mosnier E, Le Hingrat Q, Charpentier C, Corlin F, Hureau L, et al. Illegal gold miners in French Guiana: a neglected population with poor health. BMC Public Health 2017; 18: 23.
https://doi.org/10.1186/s12889-017-4557-4 DOI: https://doi.org/10.1186/s12889-017-4557-4
Douine M, Lambert Y, Mutricy L, Galindo M, Bourhy P, Saout M, et al. Émergence de zoonoses: l'orpaillage serait-il un facteur favorisant ? Infect Dis Now 2021; 51: S34-S35.
https://doi.org/10.1016/j.idnow.2021.06.075 DOI: https://doi.org/10.1016/j.idnow.2021.06.075
Oliveira IVP de M, Deps PD, Antunes JMA de P. Armadillos and leprosy: from infection to biological model. Rev Inst Med Trop São Paulo 2019; 61: e44.
https://doi.org/10.1590/s1678-9946201961044 DOI: https://doi.org/10.1590/s1678-9946201961044
da Silva Ferreira J, de Carvalho FM, Vidal Pessolani MC, de Paula Antunes JMA, de Medeiros Oliveira IVP, Ferreira Moura GH, et al. Serological and molecular detection of infection with Mycobacterium leprae in Brazilian six banded armadillos (Euphractus sexcinctus). Comp Immunol Microbiol Infect Dis 2020; 68: 101397.
https://doi.org/10.1016/j.cimid.2019.101397 DOI: https://doi.org/10.1016/j.cimid.2019.101397
Sharma R, Singh P, Loughry WJ, Lockhart JM, Inman WB, Duthie MS, et al. Zoonotic Leprosy in the Southeastern United States. Emerg Infect Dis 2015; 21: 2127-2134.
https://doi.org/10.3201/eid2112.150501 DOI: https://doi.org/10.3201/eid2112.150501
da Silva MB, Portela JM, Li W, Jackson M, Gonzalez-Juarrero M, Hidalgo AS, et al. Evidence of zoonotic leprosy in Pará, Brazilian Amazon, and risks associated with human contact or consumption of armadillos. PLoS Negl Trop Dis 2018; 12: e0006532.
https://doi.org/10.1371/journal.pntd.0006532 DOI: https://doi.org/10.1371/journal.pntd.0006532
Pescarini JM, Teixeira CSS, Silva NB da, Sanchez MN, Natividade MS da, Rodrigues LC, et al. Epidemiological characteristics and temporal trends of new leprosy cases in Brazil: 2006 to 2017. Cad Saúde Pública 2021; 37: e00130020.
https://doi.org/10.1590/0102-311x00130020 DOI: https://doi.org/10.1590/0102-311x00130020
Alter A, Alcaïs A, Abel L, Schurr E. Leprosy as a genetic model for susceptibility to common infectious diseases. Hum Genet 2008; 123: 227-235.
https://doi.org/10.1007/s00439-008-0474-z DOI: https://doi.org/10.1007/s00439-008-0474-z
Mira MT, Alcaïs A, Van Thuc N, Moraes MO, Di Flumeri C, Hong Thai V, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004; 427: 636-640.
https://doi.org/10.1038/nature02326 DOI: https://doi.org/10.1038/nature02326
Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis 2006; 193: 346-353.
https://doi.org/10.1086/499278 DOI: https://doi.org/10.1086/499278
Teles SF, Silva EA, Souza RM de, Tomimori J, Florian MC, Souza RO, et al. Association between NDO-LID and PGL-1 for leprosy and class I and II human leukocyte antigen alleles in an indigenous community in Southwest Amazon. Braz J Infect Dis 2020; 24: 296-303.
https://doi.org/10.1016/j.bjid.2020.05.009 DOI: https://doi.org/10.1016/j.bjid.2020.05.009
Lazo-Porras M, Prutsky GJ, Barrionuevo P, Tapia JC, Ugarte-Gil C, Ponce OJ, et al. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis. BMC Infect Dis 2020; 20: 62.
https://doi.org/10.1186/s12879-019-4665-0 DOI: https://doi.org/10.1186/s12879-019-4665-0
da Paz WS, Souza M do R, Tavares D dos S, de Jesus AR, dos Santos AD, do Carmo RF, et al. Impact of the COVID-19 pandemic on the diagnosis of leprosy in Brazil: An ecological and population-based study. Lancet Reg Health Am 2022; 9: 100181.
https://doi.org/10.1016/j.lana.2021.100181 DOI: https://doi.org/10.1016/j.lana.2021.100181
Lèpre/Maladie de Hansen - Prise en charge des réactions et prévention des infirmités. Conseils techniques. 2017. Available from https://www.who.int/fr/publications-detail/9789290227595.
Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-306.
https://doi.org/10.1002/cpt196563303 DOI: https://doi.org/10.1002/cpt196563303
Perez-Molina JA, Arce-Garcia O, Chamorro-Tojeiro S, Norman F, Monge-Maillo B, Comeche B, et al. Use of methotrexate for leprosy reactions. Experience of a referral center and systematic review of the literature. Travel Med Infect Dis 2020; 37: 101670
https://doi.org/10.1016/j.tmaid.2020.101670 DOI: https://doi.org/10.1016/j.tmaid.2020.101670
Pai V. Role of clofazimine in management of reactions in leprosy: a brief overview. Indian J Drugs Dermatol 2015; 1: 5.
Valentin J, Drak Alsibai K, Bertin C, Couppie P, Blaizot R. Infliximab in leprosy type 1 reaction: a case report. Int J Dermatol 2021; 60: 1285-1287.
https://doi.org/10.1111/ijd.15645 DOI: https://doi.org/10.1111/ijd.15645
Faber WR, Jensema AJ, Goldschmidt WFM. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med 2006; 355: 739.
https://doi.org/10.1056/NEJMc052955 DOI: https://doi.org/10.1056/NEJMc052955
Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis Off Publ Infect Dis Soc Am 2011; 52: e133-135.
https://doi.org/10.1093/cid/ciq213 DOI: https://doi.org/10.1093/cid/ciq213
Published
How to Cite
License
Copyright (c) 2023 Aurore Petiot, Kinan Drak Alsibai, Carmelita Dossou, Pierre Couppie, Romain Blaizot
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
